{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T21:53:51Z","timestamp":1794002031853,"version":"4.8.0"},"reference-count":75,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:00:00Z","timestamp":1745452800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016282","name":"MEI Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016282","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA266298"],"award-info":[{"award-number":["R01CA266298"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Neoplasia"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.bneo.2025.100108","type":"journal-article","created":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T12:12:48Z","timestamp":1745583168000},"page":"100108","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["The oral CDK9 inhibitor voruciclib combined with venetoclax for patients with relapsed\/refractory acute myeloid leukemia"],"prefix":"10.1016","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1652-7937","authenticated-orcid":false,"given":"Yesid","family":"Alvarado-Valero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel J.","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shira N.","family":"Dinner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Keng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2730-8593","authenticated-orcid":false,"given":"Kebede H.","family":"Begna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0702-9837","authenticated-orcid":false,"given":"Nathalie","family":"Javidi-Sharifi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1165-4766","authenticated-orcid":false,"given":"Sameem","family":"Abedin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8226-471X","authenticated-orcid":false,"given":"Monzr M.","family":"Al Malki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2513-0533","authenticated-orcid":false,"given":"Vijaya Raj","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2615-8458","authenticated-orcid":false,"given":"Prabhu","family":"Rajagopalan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra E.","family":"Wiley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard G.","family":"Ghalie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew S.","family":"Davids","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.bneo.2025.100108_bib1","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1182\/blood.V79.5.1291.1291","article-title":"bcl-2 proto-oncogene expression in normal and neoplastic human myeloid cells","volume":"79","author":"Delia","year":"1992","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bneo.2025.100108_bib2","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1182\/blood.V91.3.991","article-title":"Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse","volume":"91","author":"Kaufmann","year":"1998","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bneo.2025.100108_bib3","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1023\/A:1008255511404","article-title":"High expression of bcl-2 mRNA as a determinant of poor prognosis in acute myeloid leukemia","volume":"9","author":"Karakas","year":"1998","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.bneo.2025.100108_bib4","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1182\/blood.V81.11.3091.3091","article-title":"High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy","volume":"81","author":"Campos","year":"1993","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bneo.2025.100108_bib5","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1046\/j.1365-2141.2002.03637.x","article-title":"The anti-apoptotic genes Bcl-X(L) and Bcl-2 are over-expressed and contribute to chemoresistance of non-proliferating leukaemic CD34+ cells","volume":"118","author":"Konopleva","year":"2002","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.bneo.2025.100108_bib6","first-page":"141","article-title":"High expression of Bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy","volume":"49","author":"T\u00f3thov\u00e1","year":"2002","journal-title":"Neoplasma"},{"issue":"1","key":"10.1016\/j.bneo.2025.100108_bib7","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.bneo.2025.100108_bib8","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Eng J Med"},{"issue":"24","key":"10.1016\/j.bneo.2025.100108_bib9","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood.2020004856","article-title":"Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial","volume":"135","author":"Wei","year":"2020","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bneo.2025.100108_bib10","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/S1470-2045(20)30060-7","article-title":"Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study","volume":"21","author":"Karol","year":"2020","journal-title":"Lancet Oncol"},{"issue":"30","key":"10.1016\/j.bneo.2025.100108_bib11","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.1200\/JCO.20.00572","article-title":"Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): a phase Ib dose-escalation study of venetoclax combined with modified intensive chemotherapy","volume":"38","author":"Chua","year":"2020","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.bneo.2025.100108_bib12","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1200\/JCO.20.03736","article-title":"Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed and relapsed or refractory acute myeloid leukemia","volume":"39","author":"DiNardo","year":"2021","journal-title":"J Clin Oncol"},{"issue":"35","key":"10.1016\/j.bneo.2025.100108_bib13","doi-asserted-by":"crossref","first-page":"4048","DOI":"10.1200\/JCO.22.00602","article-title":"Venetoclax plus gilteritinib for FLT3-mutated relapsed\/refractory acute myeloid leukemia","volume":"40","author":"Daver","year":"2022","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.bneo.2025.100108_bib14","doi-asserted-by":"crossref","first-page":"3532","DOI":"10.1080\/10428194.2020.1808213","article-title":"Retreatment with venetoclax and hypomethylating agents among AML patients who have relapsed after initial response and subsequent interruption of therapy","volume":"61","author":"Othman","year":"2020","journal-title":"Leuk Lymph"},{"issue":"3","key":"10.1016\/j.bneo.2025.100108_bib15","doi-asserted-by":"crossref","first-page":"894","DOI":"10.3324\/haematol.2020.252569","article-title":"Outcomes of relapsed or refractory acute myeloid leukemia after front-line hypomethylating agent and venetoclax regimens","volume":"106","author":"Maiti","year":"2021","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.bneo.2025.100108_bib16","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.3390\/cancers14071734","article-title":"Use of venetoclax in patients with relapsed or refractory acute myeloid leukemia: the PETHEMA Registry experience","volume":"14","author":"Labrador","year":"2022","journal-title":"Cancers"},{"issue":"13","key":"10.1016\/j.bneo.2025.100108_bib17","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1080\/10428194.2022.2113530","article-title":"Dismal survival outcomes of patients with acute myeloid leukemia after failure of venetoclax with hypomethylating agents","volume":"63","author":"Zainaldin","year":"2022","journal-title":"Leuk Lymph"},{"key":"10.1016\/j.bneo.2025.100108_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2022.106942","article-title":"Efficacy of FLT3 and IDH1\/2 inhibitors in patients with acute myeloid leukemia previously treated with venetoclax","volume":"122","author":"Bewersdorf","year":"2022","journal-title":"Leuk Res"},{"issue":"1","key":"10.1016\/j.bneo.2025.100108_bib19","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3324\/haematol.2020.260331","article-title":"Targeting MCL-1 dysregulates cell metabolism and leukemia-stroma interactions and resensitizes acute myeloid leukemia to BCL-2 inhibition","volume":"107","author":"Carter","year":"2022","journal-title":"Haematologica"},{"issue":"20","key":"10.1016\/j.bneo.2025.100108_bib20","doi-asserted-by":"crossref","first-page":"6209","DOI":"10.1111\/febs.16136","article-title":"Understanding MCL1: from cellular function and regulation to pharmacological inhibition","volume":"289","author":"Sancho","year":"2022","journal-title":"FEBS J"},{"issue":"15","key":"10.1016\/j.bneo.2025.100108_bib21","doi-asserted-by":"crossref","first-page":"5204","DOI":"10.1158\/0008-5472.CAN-10-4531","article-title":"Akt-dependent glucose metabolism promotes Mcl-1 synthesis to maintain cell survival and resistance to Bcl-2 inhibition","volume":"71","author":"Coloff","year":"2011","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.bneo.2025.100108_bib22","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ccell.2019.08.005","article-title":"Mitochondrial reprogramming underlies resistance to BCL-2 inhibition in lymphoid malignancies","volume":"36","author":"Guieze","year":"2019","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.bneo.2025.100108_bib23","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/leu.2014.320","article-title":"Hypoxia-induced p38 MAPK activation reduces Mcl-1 expression and facilitates sensitivity towards BH3 mimetics in chronic lymphocytic leukemia","volume":"29","author":"Huelsemann","year":"2015","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.bneo.2025.100108_bib24","article-title":"MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K\/AKT\/mTOR activation in lymphoid malignancies [correction appears in Cell Death Dis. 2024;15(7):526]","volume":"6","author":"Choudhary","year":"2015","journal-title":"Cell Death Dis"},{"issue":"25","key":"10.1016\/j.bneo.2025.100108_bib25","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1182\/blood.2019004326","article-title":"Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL","volume":"136","author":"Haselager","year":"2020","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bneo.2025.100108_bib26","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13045-021-01079-1","article-title":"Targeting MCL-1 in cancer: current status and perspectives","volume":"14","author":"Wang","year":"2021","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.bneo.2025.100108_bib27","doi-asserted-by":"crossref","first-page":"7301","DOI":"10.2147\/OTT.S146228","article-title":"MCL-1 inhibition in cancer treatment","volume":"11","author":"Xiang","year":"2018","journal-title":"Onco Targets Ther"},{"issue":"12","key":"10.1016\/j.bneo.2025.100108_bib28","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1101\/gad.215855.113","article-title":"Deletion of MCL-1 causes lethal cardiac failure and mitochondrial dysfunction","volume":"27","author":"Wang","year":"2013","journal-title":"Genes Dev"},{"issue":"11","key":"10.1016\/j.bneo.2025.100108_bib29","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.tibs.2005.09.005","article-title":"Mammalian cyclin-dependent kinases","volume":"30","author":"Malumbres","year":"2005","journal-title":"Trends Biochem Sci"},{"issue":"5","key":"10.1016\/j.bneo.2025.100108_bib30","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nrd.2018.21","article-title":"Kinase inhibitors: the road ahead","volume":"17","author":"Ferguson","year":"2018","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"10.1016\/j.bneo.2025.100108_bib31","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1002\/jcb.26293","article-title":"CDK9: a key player in cancer and other diseases","volume":"119","author":"Franco","year":"2018","journal-title":"J Cell Biochem"},{"issue":"9","key":"10.1016\/j.bneo.2025.100108_bib32","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1158\/1535-7163.MCT-18-1023","article-title":"Cyclin-dependent kinase-9 is a therapeutic target in MYC-expressing diffuse large B-cell lymphoma","volume":"18","author":"Hashiguchi","year":"2019","journal-title":"Mol Cancer Ther"},{"issue":"17","key":"10.1016\/j.bneo.2025.100108_bib33","doi-asserted-by":"crossref","first-page":"4910","DOI":"10.1158\/1078-0432.CCR-21-0464","article-title":"Pharmacologic targeting of Mcl-1 induces mitochondrial dysfunction and apoptosis in B-cell lymphoma cells in a TP53- and BAX-dependent manner","volume":"27","author":"Liu","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.bneo.2025.100108_bib34","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.3324\/haematol.2009.017103","article-title":"Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias","volume":"95","author":"Blum","year":"2010","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.bneo.2025.100108_bib35","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1517\/13543784.2013.789859","article-title":"Cyclin-dependent kinase inhibitor therapy for hematologic malignancies","volume":"22","author":"Bose","year":"2013","journal-title":"Expert Opin Investig Drugs"},{"issue":"1","key":"10.1016\/j.bneo.2025.100108_bib36","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13046-018-0704-8","article-title":"CDK9 inhibitors in acute myeloid leukemia","volume":"37","author":"Boffo","year":"2018","journal-title":"J Exp Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.bneo.2025.100108_bib37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0143685","article-title":"Cyclin-dependent kinase inhibitor P1446A induces apoptosis in a JNK\/p38 MAPK-dependent manner in chronic lymphocytic leukemia B-cells","volume":"10","author":"Paiva","year":"2015","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.bneo.2025.100108_bib38","doi-asserted-by":"crossref","first-page":"18007","DOI":"10.1038\/s41598-017-18368-w","article-title":"Voruciclib, a clinical stage oral CDK9 inhibitor, represses MCL-1 and sensitizes high-risk diffuse large B-cell lymphoma to BCL2 inhibition","volume":"7","author":"Dey","year":"2017","journal-title":"Sci Rep"},{"issue":"suppl 15","key":"10.1016\/j.bneo.2025.100108_bib39","article-title":"Voruciclib plus venetoclax show high efficacy for CLL B cells on human stromal cells","volume":"38","author":"Lesnick","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.bneo.2025.100108_bib40","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41392-020-0112-3","article-title":"Inhibition of CDK9 by voruciclib synergistically enhances cell death induced by the Bcl-2 selective inhibitor venetoclax in preclinical models of acute myeloid leukemia","volume":"5","author":"Luedtke","year":"2020","journal-title":"Signal Transduct Target Ther"},{"issue":"suppl 15","key":"10.1016\/j.bneo.2025.100108_bib41","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1200\/jco.2012.30.15_suppl.3011","article-title":"A phase I study of selective cyclin dependent kinase inhibitor P1446A-05 administered on an intermittent schedule in patients with advanced refractory tumors","volume":"30","author":"Gupta","year":"2012","journal-title":"J Clin Oncol"},{"issue":"suppl 15","key":"10.1016\/j.bneo.2025.100108_bib42","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1200\/jco.2012.30.15_suppl.3013","article-title":"A phase I and pharmacokinetic (PK) study of continuous daily administration of P1446A-05, a potent and specific oral Cdk4 inhibitor","volume":"30","author":"Hao","year":"2012","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2025.100108_bib43","doi-asserted-by":"crossref","first-page":"4286","DOI":"10.1182\/blood-2023-179577","article-title":"A phase 1 study of the oral CDK9 inhibitor voruciclib in relapsed\/refractory (R\/R) B-cell lymphoma (NHL) or acute myeloid leukemia (AML)","volume":"142","author":"Davids","year":"2023","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2025.100108_bib44","doi-asserted-by":"crossref","first-page":"3423","DOI":"10.1182\/blood-2021-146079","article-title":"A phase 1 dose-escalation study of the oral CDK inhibitor voruciclib in patients with relapsed\/refractory B-cell malignancies or acute myeloid leukemia (AML): preliminary results of the completed dose escalation stage in AML","volume":"138","author":"Konopleva","year":"2021","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2025.100108_bib45","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1182\/blood-2024-198693","article-title":"Orally bioavailable CDK9 inhibitor voruciclib downregulates transcriptional oncogenic programs in leukemic cells from patients treated on a clinical trial","volume":"144","author":"Dominguez","year":"2024","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bneo.2025.100108_bib46","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bneo.2025.100108_bib47","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.cmpb.2010.01.007","article-title":"PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel","volume":"99","author":"Zhang","year":"2010","journal-title":"Comput Methods Programs Biomed"},{"issue":"11","key":"10.1016\/j.bneo.2025.100108_bib48","first-page":"3543","article-title":"Outcomes and genetic dynamics of acute myeloid leukemia at first relapse","volume":"109","author":"Bataller","year":"2024","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.bneo.2025.100108_bib49","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/s41408-024-01060-4","article-title":"Continuously improving outcome over time after second allogeneic stem cell transplantation in relapsed acute myeloid leukemia: an EBMT registry analysis of 1540 patients","volume":"14","author":"Schm\u00e4lter","year":"2024","journal-title":"Blood Cancer J"},{"issue":"18","key":"10.1016\/j.bneo.2025.100108_bib50","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML [published correction appears in N Engl J Med. 2022;386(19):1868]","volume":"381","author":"Perl","year":"2019","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.bneo.2025.100108_bib51","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML","volume":"378","author":"DiNardo","year":"2018","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.bneo.2025.100108_bib52","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1182\/bloodadvances.2022009411","article-title":"Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML","volume":"7","author":"de Botton","year":"2023","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.bneo.2025.100108_bib53","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1182\/blood.2021014901","article-title":"Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed\/refractory AML: a randomized phase 3 trial","volume":"141","author":"de Botton","year":"2023","journal-title":"Blood"},{"issue":"suppl 2","key":"10.1016\/j.bneo.2025.100108_bib54","doi-asserted-by":"crossref","first-page":"LBA-5","DOI":"10.1182\/blood-2023-192042","article-title":"Revumenib monotherapy in patients with relapsed\/refractory KMT2Ar acute leukemia: topline efficacy and safety results from the pivotal Augment-101 phase 2 study","volume":"142","author":"Aldoss","year":"2023","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2025.100108_bib55","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1182\/blood-2022-167412","article-title":"Update on a phase 1\/2 first-in-human study of the menin-KMT2A (MLL) inhibitor ziftomenib (KO-539) in patients with relapsed or refractory acute myeloid leukemia","volume":"140","author":"Erba","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2025.100108_bib56","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1182\/blood-2023-172422","article-title":"A first-in-human phase 1 study of the menin-KMT2A (MLL1) inhibitor JNJ-75276617 in adult patients with relapsed\/refractory acute leukemia harboring KMT2A or NPM1 alterations","volume":"142","author":"Jabbour","year":"2023","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2025.100108_bib57","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1182\/blood-2023-179252","article-title":"Phase 1\/2 first-in-human study of the menin-MLL inhibitor DSP-5336 in patients with relapsed or refractory acute leukemia","volume":"142","author":"Daver","year":"2023","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bneo.2025.100108_bib58","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41375-018-0312-9","article-title":"Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome","volume":"33","author":"Cortes","year":"2019","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.bneo.2025.100108_bib59","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1182\/bloodadvances.2020003734","article-title":"Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed\/refractory AML","volume":"5","author":"Stahl","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.bneo.2025.100108_bib60","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.649209","article-title":"Outcomes of adults with relapsed\/refractory acute myeloid leukemia treated with venetoclax plus hypomethylating agents at a Comprehensive Cancer Center","volume":"11","author":"Tenold","year":"2021","journal-title":"Front Oncol"},{"issue":"8","key":"10.1016\/j.bneo.2025.100108_bib61","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1182\/bloodadvances.2023012062","article-title":"Guadecitabine vs TC in relapsed\/refractory AML after intensive chemotherapy: a randomized phase 3 ASTRAL-2 trial","volume":"8","author":"Roboz","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.bneo.2025.100108_bib62","series-title":"Venetoclax. Prescribing information","year":"2000"},{"issue":"4","key":"10.1016\/j.bneo.2025.100108_bib63","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N Eng J Med"},{"issue":"8","key":"10.1016\/j.bneo.2025.100108_bib64","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma","volume":"35","author":"Davids","year":"2017","journal-title":"J Clin Onc"},{"issue":"3","key":"10.1016\/j.bneo.2025.100108_bib65","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1182\/blood-2014-05-573741","article-title":"Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma","volume":"125","author":"Kumar","year":"2015","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bneo.2025.100108_bib66","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1053\/j.seminoncol.2016.02.003","article-title":"Cyclin-dependent kinase inhibitors for the treatment of chronic lymphocytic leukemia","volume":"43","author":"Blachly","year":"2016","journal-title":"Semin Oncol"},{"issue":"9","key":"10.1016\/j.bneo.2025.100108_bib67","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1038\/bjc.2017.288","article-title":"Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies","volume":"117","author":"Mita","year":"2017","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.bneo.2025.100108_bib68","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1182\/blood-2006-05-020735","article-title":"Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia","volume":"109","author":"Byrd","year":"2007","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bneo.2025.100108_bib69","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s00280-013-2249-z","article-title":"Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias","volume":"72","author":"Gojo","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"issue":"12","key":"10.1016\/j.bneo.2025.100108_bib70","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1080\/10428194.2023.2244102","article-title":"Cyclin-dependent kinase-9 in B-cell malignancies: pathogenic role and therapeutic implications","volume":"64","author":"Dominguez","year":"2023","journal-title":"Leuk Lymphoma"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2025.100108_bib71","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1182\/blood-2022-167203","article-title":"Safety, tolerability, pharmacokinetics (PK) and preliminary antitumor activity of the cyclin-dependent kinase-9 (CDK9) inhibitor AZD4573 in relapsed\/refractory hematological malignancies: a phase 1 first-in-human study","volume":"140","author":"Brummendorf","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2025.100108_bib72","doi-asserted-by":"crossref","first-page":"9473","DOI":"10.1182\/blood-2022-159844","article-title":"First in human (FIH) study of GFH009, a highly selective cyclin-dependent kinase 9 (CDK9) inhibitor, in patients with relapsed\/refractory (r\/r) hematologic malignancies","volume":"140","author":"Qi","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2025.100108_bib73","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1182\/blood-2024-198686","article-title":"Phase 2a study of SLS009, a highly selective CDK9 inhibitor, in combination with azacitidine and venetoclax for relapsed\/refractory acute myeloid leukemia after prior venetoclax treatment","volume":"144","author":"Zeidner","year":"2024","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2025.100108_bib74","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1182\/blood-2024-199412","article-title":"High remission rates in relapsed\/refractory acute myeloid leukemia with QHRD107 (CDK9 inhibitor), venetoclax, and azacitidine combination therapy (107VA regimen): preliminary results of a phase 2a study","volume":"144","author":"Wu","year":"2024","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2025.100108_bib75","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/S0959-8049(22)00849-8","article-title":"A phase 1\/2, open-label, multicenter study to investigate the safety, pharmacokinetics, and efficacy of fadraciclib (CYC065), an oral CDK2\/9 inhibitor, in subjects with advanced solid tumors and lymphoma","volume":"174","author":"Piha-Paul","year":"2022","journal-title":"Eur J Cancer"}],"container-title":["Blood Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328025000433?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328025000433?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T13:10:55Z","timestamp":1756127455000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950328025000433"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":75,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S2950328025000433"],"URL":"https:\/\/doi.org\/10.1016\/j.bneo.2025.100108","relation":{},"ISSN":["2950-3280"],"issn-type":[{"value":"2950-3280","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The oral CDK9 inhibitor voruciclib combined with venetoclax for patients with relapsed\/refractory acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Blood Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bneo.2025.100108","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100108"}}